The earnings call reflected a strong financial performance with record-breaking revenue and profit growth, driven by strategic business expansions and regional success. However, significant one-time expenses and potential tariff impacts pose challenges. The outlook for future growth remains positive, with expectations of continued revenue and profit increases.

Company Guidance -

Q1 2026

During Terumo's Financial Results Presentation for the fourth quarter of fiscal year 2025, CFO Jin Hagimoto provided guidance for the upcoming year. Terumo expects revenue growth of 7% on a local currency basis, driven by company-wide expansion, particularly in Blood and Cell Technologies. Operating profit is anticipated to increase by 32%, significantly outpacing sales growth due to the absence of previous year's one-time expenses and continued profit improvement measures. The company aims to improve its operating margin by 3.3 percentage points to 18.5%. Terumo is also navigating potential impacts from U.S. reciprocal tariffs, which could affect profitability, but plans to mitigate these through strategic pricing adjustments. The company continues to invest in growth, with a focus on expanding its CDMO business and increasing production capacity, as evidenced by its recent acquisition of a WuXi Biologics factory in Germany.

Record-Breaking Revenue

Sales revenue surpassed JPY 1 trillion for the first time with a 12% increase over the previous year, driven by global demand growth and a weaker yen.

Profit Growth

Operating profit reached a record high for the fourth consecutive year and net income and free cash flow also hit record highs.

Future Growth Expectations

For fiscal 2025, revenue is expected to grow by 7% on a local currency basis, and operating profit is projected to increase by 32%.

Regional Success

All regions, especially the Americas and Europe, showed double-digit growth in local currency terms.

Cardiovascular and Blood Solutions Growth

Significant contributions to revenue growth came from the cardiovascular and Blood and Cell Technologies segments.

CDMO Business Expansion

Terumo's CDMO business is expanding globally with the acquisition of a European base, enhancing its competitive edge in the CDMO market.

Terumo (JP:4543) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

JP:4543 Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2025	2026 (Q1)	24.40 / -	22.82	―	―	―
May 14, 2025	2025 (Q4)	20.75 / 12.48	17.82	-29.97% (-5.34)
Feb 13, 2025	2025 (Q3)	25.63 / 23.96	20.03	19.62% (+3.93)
Nov 07, 2024	2025 (Q2)	22.12 / 19.75	18.495	6.79% (+1.25)
Aug 08, 2024	2025 (Q1)	20.89 / 22.82	15.14	50.73% (+7.68)
May 14, 2024	2024 (Q4)	18.61 / 17.82	12.875	38.41% (+4.95)
Feb 07, 2024	2024 (Q3)	19.77 / 20.03	19.94	0.45% (+0.09)
Nov 14, 2023	2024 (Q2)	15.82 / 18.50	11.88	55.68% (+6.62)
Aug 09, 2023	2024 (Q1)	17.66 / 15.14	14.805	2.26% (+0.34)
May 15, 2023	2023 (Q4)	16.37 / 12.88	11.315	13.79% (+1.56)		―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

JP:4543 Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 14, 2025	¥2784.50	¥2726.50	-2.08%
Feb 13, 2025	¥2779.69	¥2827.47	+1.72%
Nov 07, 2024	¥2956.87	¥2965.83	+0.30%
Aug 08, 2024	¥2463.69	¥2462.21	-0.06%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Terumo (JP:4543) report earnings?

Terumo (JP:4543) is schdueled to report earning on Aug 07, 2025, TBA (Confirmed).

What is Terumo (JP:4543) earnings time?

Terumo (JP:4543) earnings time is at Aug 07, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Terumo stock?

The P/E ratio of Terumo is N/A.

What is JP:4543 EPS forecast?

JP:4543 EPS forecast for the fiscal quarter 2026 (Q1) is 24.4.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing